PMID- 35281069 OWN - NLM STAT- MEDLINE DCOM- 20220502 LR - 20220531 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Identification and Validation of Immune Infiltration Phenotypes in Laryngeal Squamous Cell Carcinoma by Integrative Multi-Omics Analysis. PG - 843467 LID - 10.3389/fimmu.2022.843467 [doi] LID - 843467 AB - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the world's most common head and neck cancer. However, the immune infiltration phenotypes of LSCC have not been well investigated. METHODS: The multi-omics data of LSCC were obtained from the TCGA (n=111) and GEO (n=57) datasets. The infiltrations of the 24 immune cell populations were calculated using the GSVA method. Then LSCC samples with different immune cell infiltrating patterns were clustered, and the multi-omics differences were investigated. RESULTS: Patients were clustered into the high-infiltration and low-infiltration groups. The infiltration scores of most immune cells were higher in the high-infiltration group. Patients with high-infiltration phenotype have high N and TNM stages but better survival, as well as less mutated COL11A1 and MUC17. Common targets of immunotherapies such as PD1, PDL1, LAG3, and CTLA4 were significantly up-regulated in the high-infiltration group. The differentially expressed genes were mainly enriched in several immune-related GOs and KEGG pathways. Based on the genes, miRNAs, and lncRNAs differentially expressed in both the TCGA and GEO cohorts, we built a ceRNA network, in which BTN3A1, CCR1, miR-149-5p, and so on, located at the center. A predictive model was also constructed to calculate a patient's immune infiltration phenotype using 16 genes' expression values, showing excellent accuracy and specificity in the TCGA and GEO cohorts. CONCLUSIONS: In this study, the immune infiltration phenotypes of LSCC and the corresponding multi-omics differences were explored. Our model might be valuable to predicting immunotherapy's outcome. CI - Copyright (c) 2022 Yan, Song, Yang, Zou, Zhu and Wang. FAU - Yan, Li AU - Yan L AD - Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. FAU - Song, Xiaole AU - Song X AD - Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. FAU - Yang, Gang AU - Yang G AD - Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. FAU - Zou, Lifen AU - Zou L AD - Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. FAU - Zhu, Yi AU - Zhu Y AD - Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. FAU - Wang, Xiaoshen AU - Wang X AD - Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220224 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Antigens, CD) RN - 0 (BTN3A1 protein, human) RN - 0 (Butyrophilins) RN - 0 (MIRN149 microRNA, human) RN - 0 (MicroRNAs) SB - IM MH - Antigens, CD MH - Butyrophilins/genetics MH - Gene Expression Regulation, Neoplastic MH - Humans MH - *Laryngeal Neoplasms/genetics MH - *MicroRNAs MH - Phenotype MH - *Squamous Cell Carcinoma of Head and Neck/genetics PMC - PMC8907422 OTO - NOTNLM OT - TCGA OT - head and neck cancer OT - immune infiltration OT - immunology OT - laryngeal COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/15 06:00 MHDA- 2022/05/03 06:00 PMCR- 2022/01/01 CRDT- 2022/03/14 05:17 PHST- 2021/12/26 00:00 [received] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/03/14 05:17 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/05/03 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.843467 [doi] PST - epublish SO - Front Immunol. 2022 Feb 24;13:843467. doi: 10.3389/fimmu.2022.843467. eCollection 2022.